Search Results - "Kamalakar, Rajesh"

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia by Pratz, Keith W., Panayiotidis, Panayiotis, Recher, Christian, Wei, Xudong, Jonas, Brian A., Montesinos, Pau, Ivanov, Vladimir, Schuh, Andre C., DiNardo, Courtney D., Novak, Jan, Pejsa, Vlatko, Stevens, Don, Yeh, Su-Peng, Kim, Inho, Turgut, Mehmet, Fracchiolla, Nicola, Yamamoto, Kazuhito, Ofran, Yishai, Wei, Andrew H., Bui, Cat N., Benjamin, Katy, Kamalakar, Rajesh, Potluri, Jalaja, Mendes, Wellington, Devine, Jacob, Fiedler, Walter

“…Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received…”
Get full text

P1176: CLINICAL OUTCOMES OF NOVEL THERAPIES IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA by Crombie, Jennifer, Jun, Monika, Wang, Tongsheng, Mutebi, Alex, Wang, Anthony, Chibber, Anindit, Kamalakar, Rajesh, Ukropec, Jon, Blaedel, Julie, Kalsekar, Anupama

Get full text

S310: VENETOCLAX PLUS AZACITIDINE DELAYS DETERIORATION OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: VIALE-A LONG-TERM FOLLOW UP by Pratz, Keith, Lai, Catherine, Jonas, Brian A., Dinardo, Courtney, Bui, Cat N., Kamalakar, Rajesh, Potluri, Jalaja, Chang, Wei-Han, Sen, Rohini, Leblanc, Thomas W

Get full text

Real-World Treatment Patterns and Outcomes of Daratumumab Retreatment in Multiple Myeloma in the United States by Girvan, Allicia, Yu, Junhua, Emechebe, Nnadozie, Kamalakar, Rajesh, Luo, Yan

Get full text

Treatment Patterns and Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Receiving ≥3 Lines of Therapy: A Real-World Evaluation in the United States by Girvan, Allicia, Yu, Junhua, Kamalakar, Rajesh, Mearns, Elizabeth S., Nixon, Michael, Cornell, Robert F.

Get full text

Economic Burden of Multiple Myeloma: Results from a Large Employer-Sponsored Real-World Administrative Claims Database, 2012 to 2018 by Tran, Dao, Kamalakar, Rajesh, Manthena, Shivaji, Karve, Sudeep

“…Introduction: Multiple myeloma (MM) is a relatively rare, but serious neoplasm of terminally differentiated B-lymphocytes. Patients with MM experience clinical…”
Get full text

Real-World Progression-Free Survival and Treatment Patterns for t(11;14) Positive Patients with Multiple Myeloma with at Least 2 Prior Lines of Treatment by Girvan, Allicia, Martins, Daniel, Yu, Junhua, Ng, Sophia, Kamalakar, Rajesh, Zafar, Faiza, Tulsian, Seema, Cornell, Robert F., Samir, Mohamed

“…Background : Multiple myeloma (MM) is a subclonal disease characterized by large heterogeneity with a complex treatment landscape. Patients with MM have a…”
Get full text

Psychometric Validation and Meaningful Change Threshold Determination of EORTC QLQ-C30 Physical Functioning and Promis SF v1.0-Fatigue 7a Functional Domain in Patients with High-Risk Myelodysplastic Syndromes Treated with Venetoclax and Azacitidine by Lyons, Roger M., Foster, Brandon, Jewett, Adrian, Liu, Liu, Sen, Rohini, Bui, Cat N., Kamalakar, Rajesh, Potluri, Jalaja

“…Background : Patients with myelodysplastic syndromes (MDS) can experience fatigue, infection, anemia, bruising, and bleeding. Fatigue and physical functioning…”
Get full text

Follicular Lymphoma Treatment Patterns and Outcomes over Time: A Real-World Analysis in the United States by Phillips, Tycel, Yu, Junhua, Kamalakar, Rajesh, Davies, Kalatu R., Mutebi, Alex, Bains Chawla, Savreet, Arnette, Donald, Quadri, Syed, Wang, Anthony

Get full text

Real-World Response Rates across Lines of Therapy Among Patients with Relapsed/Refractory Follicular Lymphoma by Philips, Tycel, Sehn, Laurie H., Wang, Anthony, Yu, Junhua, Marchlewicz, Elizabeth H., Kamalakar, Rajesh, Sail, Kavita, Arnette, Donald, Yang, Shibing, Mutebi, Alex, Rivas Navarro, Fernando, Salles, Gilles

“…Background: Follicular lymphoma (FL) is the most common indolent subtype of non-Hodgkin lymphoma. Despite the generally indolent nature of the condition, there…”
Get full text

Real-world outcomes with novel therapies in R/R DLBCL by Crombie, Jennifer Leigh, Jun, Monika P., Wang, Tongsheng, Mutebi, Alex, Wang, Anthony, Chibber, Anindit, Kamalakar, Rajesh, Ukropec, Jon, Blædel, Julie, Kalsekar, Anupama

“…7552 Background: Outcomes have historically been poor for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Despite an increase in…”
Get full text

Racial and ethnic representation in large B-cell lymphoma trials and real-world databases by Munoz, Javier, Mutebi, Alex, Wang, Tongsheng, Zhang, Guihua, Yu, Junhua, He, Jing, Chibber, Anindit, Kamalakar, Rajesh, Jun, Monika P., Adejumo, Kelechi, Yang, Shibing, Kalsekar, Anupama

“…e19530 Background: In large B-cell lymphoma (LBCL) trials, racial and ethnic representation is difficult to determine due to underreporting in some regions, or…”
Get full text

Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma by Crombie, Jennifer L, Jun, Monika, Wang, Tongsheng, Mutebi, Alex, Wang, Anthony, Chhibber, Anindit, Kamalakar, Rajesh, Ukropec, Jon, Blaedel, Julie, Kalsekar, Anupama

“…This study used COTA de-identified data (2010-2021) of patients in the US to explore outcomes of novel therapies in relapsed/refractory (R/R) diffuse large…”
Get full text

Real-World Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Standard of Care: A Cota Database Analysis by Ip, Andrew, Mutebi, Alex, Wang, Tongsheng, Jun, Monika P., Kalsekar, Anupama, Rivas Navarro, Fernando, Wang, Anthony, Kamalakar, Rajesh, Sacchi, Mariana, Elliott, Brian

Get full text

Health Care Resource Utilization and Costs of CAR T Therapy in Patients with Large B-Cell Lymphoma: A Retrospective US Claims Database Analysis by Davies, Kalatu R., Kamalakar, Rajesh, Yu, Junhua, Huang, Yinan, Wang, Anthony, Sail, Kavita, Doerr, Thomas, Sharmokh, Simon, Mutebi, Alex, Salles, Gilles

Get full text

Real-World Treatment Patterns and Transfusion Burden Among Newly Diagnosed Older Adults with Acute Myeloid Leukemia by Zeidan, Amer M., Cheng, Wei-Han, Kamalakar, Rajesh, Miller, Catherine, Bui, Cat N., Montez, Melissa, Yee, Tracy, Wu, Zheng, Huntington, Scott F.

Get full text

P-072 Health Care Resource Utilization and Economic Burden of Cytokine Release Syndrome Management in Patients With Multiple Myeloma Receiving CAR-T Cell and Bispecific Antibody Therapies by Rodriguez-Valdes, Cesar, Jiao, Shiyin, Yu, Junhua, Kamalakar, Rajesh, Cornell, R. Frank, Sail, Kavita, Bueno, Orlando, Costa, Luciano

Get full text

Transfusion Requirements and Hospitalization during First Line Treatment Among Newly Diagnosed Acute Myeloid Leukemia Patients Who Were Ineligible for Intensive Chemotherapy by Bui, Cat N., Marshall, Thomas, Kamalakar, Rajesh, Posadas, Tracey, Potluri, Jalaja

“…Background: Newly diagnosed acute myeloid leukemia (ND AML) patients (pts) ineligible for intensive chemotherapy have limited treatment options. Most commonly…”
Get full text

Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis by Ip, Andrew, Mutebi, Alex, Wang, Tongsheng, Jun, Monika, Kalsekar, Anupama, Navarro, Fernando Rivas, Wang, Anthony, Kamalakar, Rajesh, Sacchi, Mariana, Elliott, Brian

“…Introduction Despite new therapies for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treatments with chemotherapy, single-agent…”
Get full text

Treatment Outcomes Among Chronic Lymphocytic Leukemia Patients with 17p Deletion or TP53 Mutation in Argentina: A Retrospective Chart Review by Pavlovsky, Miguel A., Sail, Kavita, Chaves, Leonardo Passos, Kamalakar, Rajesh, Ma, Xiaojing, Brandalise, Patricia, Chiattone, Carlos

“…Introduction Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries. CLL patients with 17p deletion and/or TP53 mutation…”
Get full text